RestorGenex Announces Issuance of European Patent for its Dermatology Program

RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that the European Patent Office has issued to RestorGenex European Patent No. 2364700 entitled "Compositions and Methods to Treat Skin Diseases Characterized by Cellular Proliferation and Angiogenesis." The patent is directed to use of RES-529, as well as other small molecules, for preventing or treating skin diseases, as well as on the composition of matter of RES-529. RES-529 is a first-in-class allosteric dissociative TORC1/TORC2 inhibitor of the PI3K pathway, and is RestorGenex’s lead candidate in development for the treatment of diseases involving cell proliferation and angiogenesis.

The patent adds EU protection to RestorGenex’s intellectual property portfolio related to RES-529 that includes U.S. Patent No. 8,475,776 which provides both composition of matter and method of use protection for RES-529 in the United States. Related patents also have been issued in China, Australia, and Mexico. Patent applications are pending in major pharmaceutical markets worldwide including Japan and Canada for composition of matter and use for indications including ophthalmology, oncology, dermatology, fibrotic diseases and biodefense.

“RES-529, as a first-in-class allosteric inhibitor of TORC1/TORC2, has shown the ability to dissociate both TORC1 and TORC2 complexes thus being the only true TORC1/TORC2 inhibitor within the field of PI3K inhibitors. We believe such utility will ultimately show superiority of RES-529 in the clinic compared to other PI3K inhibitors under development,” commented David Sherris, Ph.D, chief scientific officer of RestorGenex.

About RES-529

RES-529 was developed from a non-steroidal, small molecule drug library through computational design, synthetic and medicinal chemistry. RES-529 is the result of three generations of computational design work. Through a series of in vitro and in vivo animal models, RES-529 has been shown activity in a variety of cancer types due to its ability to target and inhibit the PI3K/Akt/mTOR signal transduction pathway, specifically as a first-in-class allosteric, dissociative inhibitor of both TORC1 and TORC2.

About RestorGenex Corporation

RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. RestorGenex’s lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a “soft” anti-androgen compound for the treatment of acne vulgaris. RestorGenex’s novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information please see: www.restorgenex.com.

Forward-Looking Statements

Certain statements in this release are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the clinical effectiveness and potential of RES-529 and other statements that are not historical in nature, particularly those that utilize terminology such as “will,” “believe,” “may,” “intends,” “expects,” “future,” “believes,” “continue,” other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause RestorGenex’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include, among others, uncertainties regarding uncertainties involved in clinical testing, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, RestorGenex’s ability to license out its existing products and technologies and license in additional products and technologies and the terms of such licenses; and other risks and uncertainties described in RestorGenex´s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K/A, subsequent quarterly reports on Form 10-Q and final prospectus dated July 31, 2014. All forward-looking statements in this release speak only as of the date of this release and are based on RestorGenex´s current beliefs and expectations. RestorGenex undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.